UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): June 7, 2005
ENZO BIOCHEM, INC.
---------------------------------------------------------
(Exact Name of Registrant as Specified in Its Charter)
NEW YORK
--------------------------------------------
(State or Other Jurisdiction of Incorporation)
1-09974 13-2866202
(Commission File Number) (IRS Employer Identification No.)
60 EXECUTIVE BOULEVARD
FARMINGDALE, NEW YORK 11735
-----------------------------------------
(Address of Principal Executive Offices)
(631) 755-5500
-----------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
NOT APPLICABLE
------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 8.01 OTHER EVENTS
On June 7, 2005, Enzo Biochem, Inc. (the "Company") issued a press release
announcing it will hold a conference call to discuss its fiscal 2005 third
quarter results on Thursday, June 9, 2005, at 4:45 PM ET. A copy of the press
release is furnished as Exhibit 99.1 to this Current Report and is incorporated
by reference herein.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(c)
Exhibit No. Description
------------ -----------
99.1 Press Release of Enzo Biochem, Inc. dated June 7, 2005.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ENZO BIOCHEM, INC.
By: /s/ Barry Weiner
-------------------------------------
Barry Weiner
President and Chief Financial Officer
Dated: June 7, 2005
EXHIBIT INDEX
Exhibit No. Description
99.1 Press Release of Enzo Biochem, Inc. dated June 7, 2005.